Genetix Grp Share Discussion Threads

[lovecustard] 14/5/2003 08:36

last mm on offer

[westex] 13/5/2003 16:00

Any idea what the cash per share is ? Is it more than the cap.?

[westex] 13/5/2003 15:59

MBO soon too i reckon, whats the cash per share?

[lovecustard] 13/5/2003 08:25

cash rich and generative, starting to recover at 28p, last mm o 29 then its 32p fellas,fyb as they used to say

[lovecustard] 13/5/2003 08:20

i think an MBO is likely on this cash rich biz

[lovecustard] 13/5/2003 08:20

last mm at 29, thos ones ready to fly

[qazwsx123] 21/4/2003 11:54

If you are interested in biotechs, you may be interested in the expected news from Alizyme (AZM) as follows:

1) May 2003: PIIb results for Renzapride treating c-IBS (514 patients).
2) Mid 2003: first licensing deal for Colal-Pred.
3) Oct 2003: PIIb results for Renzapride treating m-IBS (170 patients).
4) Oct 2003: PIIb results for ATL-962 treating obesity (340 patients).
5) H2 2003: PIIa results for ATL-104 treating mucositis.
6) Q4 2003: further pharmacokinetic/dynamic results for Renzapride (48 patients in USA).
------------------------------------------------------------------------------
7) 2004: licensing deals for Renzapride treating c-IBS & m-IBS.
8) 2004: licensing deal for ATL-962 treating obesity.
9) H2 2004: PIII results for Colal-Pred (active disease and remission trials).
------------------------------------------------------------------------------
10) H1 2005: Colal-Pred on market.

Sales of Colal-Pred treating active ulcerative colitis should exceed £100m pa, as should sales for maintaining remission; generating revenues of approximately £30 million pa for the Company (i.e. 15% royalties on annual sales of approximately £200 million) (Investor's Chronicle suggested 30% royalties, but that may be on the high side).

Sales of Renzapride, ATL-962 and ATL-104, should generate much higher revenues for Alizyme.

Brett Pollard of analysts Seymour Pierce estimates the licensing deals anticipated for Colal-Pred, Renzapride and ATL-962, during 2003/04, could bring in £50 million cash.

[boram] 02/3/2003 17:05

Genetix, Finals are out on Tuesday 4th.

[finmac] 22/7/2002 09:56

Sound like a promising announcement today, let hope it motivates this share North.

[pfb5] 14/7/2002 13:18

FINMAC - two things spring to mind.

(i) there's not much trade in this one, it's a small company with a limited market and not much to shout about. (ii)it's in the wrong sector, by all accounts.

Very often labelled as 'pharmaceutical' they actually manufacture machinery which is used in the analysis of DNA and now that the Human Genome Project has finished the gene map, GTX is moving in to equipment for the field of proteomics which is the next stage.

Apart from Sept 11th general crash, they announced last October that targets for the year would not be met due to the effects of that catastrophe (see and the price plummetted that day without any significant trades that I could see. Now I'm not an expert at this but it looks to me like the market-makers moved the price, not the market supply & demand.

Sales were still up but not as much as anticipated, so profit was down, however note that there was a massive increase in R&D. Interims are due 29th July when we'll see how this year looks, but I don't see much upwards movement being likely as the market is so small - unless the Corporate Broker does some stirring up.

I've got a holding which I'm sitting on in the hope of improvement, I don't see any reason to bail out, it just needs a long term view in my opinion.

[finmac] 11/7/2002 22:24

Anyone any idea why this share as started to fall,there appears no news to justify it, and it is falling more than the market trend.

[finmac] 08/4/2002 15:46

Anyone any Idea what report and accounts say, issued today

[finmac] 14/3/2002 00:37

This share is realy moving North this morning

[calleva] 15/1/2002 16:41

Genetix Group plc will be announcing its preliminary results for the year
ended 31 December 2001 on Monday 4 March 2002.

[finmac] 26/10/2001 21:58

This company looks a good buy after the drop in share price on the recent profits warning. If you look at the fundementals they have plenty of cash and potential. Worth having a good lookat to get in at the right price.It is also well up today on the Nasdaq.
Finmac

[finmac] 23/10/2001 15:04

I agree this share has potential after the drop yesterday and I have bought at .84 hoping for a good gain.
Finmac

[kendodo] 22/10/2001 15:55

I have been looking at this share for a long time and have just bought some at 89p after profit warning. I suggest other people take notice and do the same this is an excellent chance to get in to a good company at a low price.

[angler] 31/7/2001 18:11

Pippin: you're right, business is moving forward. Big concern is the dilutive effect of Director's variable earnout if profits to 31 Dec 2001 meet/exceed agreed levels. H1 figures suggest that profits are on course for at least a 35% earnout with corresponding reduction on eps. One to watch, especially if they can roll out product in double quick time.

[pippin] 31/7/2001 08:23

Nothing wrong here! One stock hammered by the tech nightmare that doesn't seem to deserve its price being smashed.

[jimibt] 30/7/2001 20:53

it certainly hasn't been lower:) results tomorrow!! could well be interesting but I doubt if the new deals will be factored in as the accounts are up to 30th june.

We'll see tho' good luck!!

[boram] 30/7/2001 20:50

Genetix is a company that has recently lunch new products and
licenced software, it looks like it is a healthy company which is
growing. This is one to watch.

[zzaxx99] 10/7/2001 08:16

'Genetix Group plc (LSE: GTX), the genomics and proteomics technology group, today announces a further expansion of its range of genomic tools with the launch of an effective Clone Library Management System.

Following the sequencing of the human genome and genomes from other organisms, many research laboratories are challenged by the number of DNA samples that need to be archived. A small bacterial genome will produce over 100,000 sequences. The Genetix QSelect will allow such a library to be copied in a few hours, a process that usually takes several working days. Furthermore, single samples can be identified and picked for further analysis in a matter of minutes, a dramatic improvement in speed and accuracy.

The QSelect is the latest in a range of high precision robots designed to assist the researcher in discovering the function of genes and proteins in the laboratory. Like the MegaPix, launched at the end of 2000, it is a high throughput, highly automated robot which complements Genetix's existing range of products in the area of genomic analysis....'

[zzaxx99] 10/7/2001 08:15

'Genetix Group plc (LSE: GTX), the genomics and proteomics technology group, today announces a further expansion of its range of genomic tools with the launch of an effective Clone Library Management System.

Following the sequencing of the human genome and genomes from other organisms, many research laboratories are challenged by the number of DNA samples that need to be archived. A small bacterial genome will produce over 100,000 sequences. The Genetix QSelect will allow such a library to be copied in a few hours, a process that usually takes several working days. Furthermore, single samples can be identified and picked for further analysis in a matter of minutes, a dramatic improvement in speed and accuracy.

The QSelect is the latest in a range of high precision robots designed to assist the researcher in discovering the function of genes and proteins in the laboratory. Like the MegaPix, launched at the end of 2000, it is a high throughput, highly automated robot which complements Genetix's existing range of products in the area of genomic analysis....'

[sed] 27/3/2001 11:50

why has this stock not moved recently??..soz..im new to this game

[soundbite] 20/3/2001 09:15

Watching with interest!!!!

Price action/volume/news flow(lack of) all point to something - corporate action/big announcement?

Consider:
1.Massive chunks totalling 2 million (biggest vol since coming to mkt) shares traded just before yesterday's close
2.Desperate to avoid press attention as Chester says
3.Steady riser against general mkt gloom

Added to my holding this morning and now awaiting developments.